{"drugs":["Cholac","Constilac","Constulose","Enulose","Generlac","Kristalose","Lactulose"],"mono":{"0":{"id":"329396-s-0","title":"Generic Names","mono":"Lactulose"},"1":{"id":"329396-s-1","title":"Dosing and Indications","sub":[{"id":"329396-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Constipation:<\/b> 15 to 30 mL (10 to 20 grams lactulose) ORALLY once daily for 24 to 48 hours; may increase to 60 mL (40 grams lactulose)\/day if needed<\/li><li><b>Hepatic encephalopathy; Treatment and Prophylaxis:<\/b> rapid laxation during the initial phase, 30 to 45 mL ORALLY every 1 hr until laxative effect is achieved, then reduce the dose to 30 to 45 mL (containing 20 to 30 grams lactulose) ORALLY 3 to 4 times daily adjusted every 1 to 2 days to achieve 2 to 3 soft formed stools daily.<\/li><li><b>Hepatic encephalopathy; Treatment and Prophylaxis:<\/b> continuous long-term therapy, 30 to 45 mL ORALLY (containing 20 to 30 grams lactulose) 3 to 4 times daily adjusted every 1 to 2 days to achieve 2 to 3 soft formed stools daily<\/li><li><b>Hepatic encephalopathy; Treatment and Prophylaxis:<\/b> lactulose 300 mL mixed with 700 mL water or normal saline and retained RECTALLY for 30 to 60 min and repeated every 4 to 6 hr as a retention enema via a rectal balloon catheter. If the enema is inadvertently evacuated too promptly, it may be repeated immediately. When the oral route is viable, initiate oral administration before rectal administration is terminated<\/li><\/ul>"},{"id":"329396-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy have not been established in pediatric patients<\/li><li><b>Constipation:<\/b> (6 months to 3 years) 5 to 10 mL (3.33 to 6.66 grams lactulose) ORALLY daily<\/li><li><b>Hepatic encephalopathy; Treatment and Prophylaxis:<\/b> (infants) initial, 2.5 to 10 mL\/day ORALLY in divided doses to achieve 2 to 3 soft formed stools daily<\/li><li><b>Hepatic encephalopathy; Treatment and Prophylaxis:<\/b> (children and adolescents) 40 to 90 mL\/day ORALLY in divided doses to achieve 2 to 3 soft formed stools daily<\/li><\/ul>"},{"id":"329396-s-1-6","title":"Dose Adjustments","mono":"<b>diarrhea in children:<\/b> reduce the dose immediately and if diarrhea persists, discontinue therapy "},{"id":"329396-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Constipation<\/li><li>Hepatic encephalopathy; Treatment and Prophylaxis<\/li><\/ul>"}]},"3":{"id":"329396-s-3","title":"Contraindications\/Warnings","sub":[{"id":"329396-s-3-9","title":"Contraindications","mono":"low-galactose diet requirement; contains galactose (less than 1.6 g\/15 mL) <br\/>"},{"id":"329396-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use with other laxatives, especially early in therapy, is not recommended (Enulose(R))<\/li><li>diabetes; contains galactose (less than 1.6 g\/15 mL) and lactose (less than 1.2 g\/15 mL)<\/li><li>elderly and\/or debilitated treated for more than 6 months; monitoring recommended<\/li><li>electrocautery procedures during proctoscopy or colonoscopy; theoretical risk for explosive reaction that may result from significant hydrogen gas concentration in presence of electrical spark; bowel cleansing with a nonfermentable solution recommended<\/li><li>infants may develop hyponatremia and dehydration (Enulose(R))<\/li><\/ul>"},{"id":"329396-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"329396-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"329396-s-4","title":"Drug Interactions","sub":{"1":{"id":"329396-s-4-14","title":"Major","mono":"<ul><li>Droperidol (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Licorice (theoretical)<\/li><\/ul>"},"2":{"id":"329396-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Dicumarol (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}}},"5":{"id":"329396-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Bloating symptom, Diarrhea, Epigastric pain, Flatulence, Nausea, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Cramp<\/li><\/ul><b>Serious<\/b><br\/><b>Endocrine metabolic:<\/b>Hypernatremia, Hypokalemia<br\/>"},"6":{"id":"329396-s-6","title":"Drug Name Info","sub":{"0":{"id":"329396-s-6-17","title":"US Trade Names","mono":"<ul><li>Kristalose<\/li><li>Cholac<\/li><li>Constilac<\/li><li>Constulose<\/li><li>Generlac<\/li><li>Enulose<\/li><\/ul>"},"2":{"id":"329396-s-6-19","title":"Class","mono":"Laxative, Hyperosmotic<br\/>"},"3":{"id":"329396-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"329396-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"329396-s-7","title":"Mechanism Of Action","mono":"Lactulose is a synthetic disaccharide used for the treatment of constipation. Bacteria in the colon degrade lactulose into lactic acid, acetic acid and formic acid resulting in an increase in osmotic pressure and acidification of intestinal contents which in turn, softens the stool by promoting stool water content.<br\/>"},"8":{"id":"329396-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"329396-s-8-23","title":"Absorption","mono":"Oral: poorly absorbed <br\/>"},"3":{"id":"329396-s-8-26","title":"Excretion","mono":"Renal: 3% or less <br\/>"}}},"9":{"id":"329396-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>may be mixed with fruit juice, water, or milk to improve taste <br\/>"},"10":{"id":"329396-s-10","title":"Monitoring","mono":"<ul><li>improvement of signs and symptoms of constipation such as the number and the consistency of bowel movements<\/li><li>serum electrolytes (potassium, chloride, carbon dioxide) in elderly or debilitated patients on long term (6 months or more) therapy<\/li><\/ul>"},"11":{"id":"329396-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Solution: 10 GM\/15 ML<\/li><li>Oral Syrup: 10 GM\/15 ML<\/li><\/ul><\/li><li><b>Constulose<\/b><br\/>Oral Solution: 10 GM\/15 ML<br\/><\/li><li><b>Enulose<\/b><br\/>Oral Solution: 10 GM\/15 ML<br\/><\/li><li><b>Generlac<\/b><br\/>Oral Solution: 10 GM\/15 ML<br\/><\/li><li><b>Kristalose<\/b><br\/>Oral Powder for Suspension: 10 GM\/Packet, 20 GM\/Packet<br\/><\/li><\/ul>"},"13":{"id":"329396-s-13","title":"Clinical Teaching","mono":"<ul><li>If patient is using drug to relive constipation, inform patient that drug effects may not be seen for 24 to 48 h.<\/li><li> This drug may cause bloating, epigastric pain, flatulence, nausea, vomiting, or cramping.<\/li><li>Instruct patient to report diarrhea, as dose may need adjustment.<\/li><li>Patient may mix drug with fruit juice, water, or milk.<\/li><\/ul>"}}}